SSRI AGREEMENT

This Memorandum of Understanding ("MOU") is entered into by the National Air Traffic Controllers Association, AFL-CIO ("NATCA" or "the Union") and the Federal Aviation Administration ("FAA" or "the Agency"), herein collectively referred to as "the Parties." This MOU represents the complete understanding of the Parties at the national level concerning the selective serotonin reuptake inhibitor (SSRI) program and is applicable to all NATCA Bargaining Unit Employees (BUEs) that require a medical clearance.

Section 1. In accordance with the FAA ATCS - SSRI Guidance updated on June 7, 2017 employees may be considered for a special consideration medical clearance while being treated with selective serotonin reuptake inhibitors (SSRIs) as identified in the "Guide for Aviation Medical Examiners". Currently the following SSRIs have been approved: Fluoxetine (Prozac), Sertraline (Zoloft), Citalopram (Celexa), or Escitalopram (Lexapro). The list of permitted SSRIs may be expanded if, in the future, the FAA approves additional SSRIs based on the safety of the drug(s).

Section 2. An employee who meets their obligations and timely submits all required medical information as described in Appendix C of FAA Order 3930.3, and through no fault of the employee, there is a lapse of the employee's medical clearance, the employee will not have their operational schedule changed or have a loss of, charge to, or reduction of leave, pay or benefits.

Upon review of all the necessary medical information required to make a medical determination, if the RFS requests additional information from the employee, or determines that the employee is no longer eligible for a special consideration clearance, the provisions of this Section shall cease to apply upon notification to the employee and the employee's Air Traffic Manager.

Section 3. Nothing in this Agreement waives any rights employees and the Union would otherwise have under the NATCA/FAA Collective Bargaining Agreements, Memoranda of Understanding, applicable laws, rules, regulations and past practice.

Section 4. This Agreement shall remain in full force and effect for the life of the currently applicable Collective Bargaining Agreement.

Signed this 18th day of January 2018.

For the Union:

Dean Iacopelli

Ryan Smith

For the Agency:

Ennannea

Suzanne Gould, AJG-L1

SSRI Agreement Page 1 of 1